- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.03. | Sera Prognostics, Inc.: Sera Prognostics Reports Fourth Quarter 2024 Financial Results | 90 | PR Newswire | SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health... ► Artikel lesen | |
| 19.03. | Sera Prognostics appoints Jeff Elliott to board | 1 | Investing.com | ||
| 19.03. | SERA PROGNOSTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 19.03. | Sera Prognostics GAAP EPS of -$0.25 misses by $0.01, revenue of $0.02M | 4 | Seeking Alpha | ||
| 19.03. | SERA PROGNOSTICS, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
| 19.03. | SERA PROGNOSTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.03. | Sera Prognostics A: Finanzielle Herausforderungen und Zukunftsaussichten | 1 | IT BOLTWISE | ||
| 10.03. | Sera Prognostics CFO verkauft Aktien für 19.850 US-Dollar | 1 | Investing.com Deutsch | ||
| SERA PROGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 10.03. | Sera Prognostics CIO verkauft Unternehmensaktien im Wert von 16.115 US-Dollar | 2 | Investing.com Deutsch | ||
| 10.03. | Sera Prognostics CEO veräußert Aktien im Wert von 122.454 US-Dollar | 5 | Investing.com Deutsch | ||
| 14.02. | Sera Prognostics CFO verkauft Aktien im Wert von 27.090 US-Dollar | 1 | Investing.com Deutsch | ||
| 14.02. | Wissenschaftlicher Leiter von Sera Prognostics verkauft Aktien für 27.090 US-Dollar | 1 | Investing.com Deutsch | ||
| 11.02. | Sera Prognostics dips 5%, prices $50M offering | 2 | Seeking Alpha | ||
| 10.02. | Sera Prognostics announces proposed public offering | 2 | Seeking Alpha | ||
| 10.02. | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 31.01. | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 07.01. | SALT LAKE CITY - Sera Prognostics-Direktor verkauft Aktien im Wert von 769 US-Dollar | 1 | Investing.com Deutsch | ||
| 07.01. | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 06.11.24 | Sera Prognostics, Inc.: Sera Prognostics Reports Third Quarter 2024 Financial Results | 79 | PR Newswire | SALT LAKE CITY, Nov. 6, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health... ► Artikel lesen | |
| 06.11.24 | SERA PROGNOSTICS, INC. - 10-Q, Quarterly Report | - | SEC Filings |
Seite:
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,485 | -0,67 % | NanoRepro Aktie: Starker Kurs - erfreuliche Aussichten! | Die Biotech-Aktie verzeichnet deutliche Zugewinne und überwindet wichtige Widerstandslinien, während ein Führungsmitglied mit eigenem Kapitaleinsatz Vertrauen demonstriert. Die NanoRePro AG verzeichnete... ► Artikel lesen | |
| OCUGEN | 0,597 | -6,14 % | Ocugen: Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200-a Novel Fusion Protein for Diabetic Macular Edema | OCU200 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reportedDosing of the second cohort has been approved MALVERN, Pa., March 18... ► Artikel lesen | |
| VIKING THERAPEUTICS | 23,000 | -2,91 % | Viking Therapeutics (NASDAQ:VKTX) Sets New 12-Month Low - Time to Sell? | ||
| COSCIENS BIOPHARMA | 2,500 | -6,02 % | COSCIENS Biopharma Inc. - 6-K, Report of foreign issuer | ||
| SCORPIUS | 0,136 | -13,05 % | Scorpius Holdings, Inc. - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | ||
| BIOCRYST PHARMACEUTICALS | 6,202 | -9,38 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
| VAXART | 0,347 | +6,17 % | Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") today announced that on March 24, 2025, the independent members of the Board... ► Artikel lesen | |
| REDHILL BIOPHARMA | 2,230 | -8,98 % | RedHill Biopharma Ltd.: RedHill Biopharma to Submit FDA-Approved Talicia for UK Marketing Authorisation | RedHill plans to submit UK MAA1 for Talicia for H. pylori infection, using MHRA's2 new fast-track approval process, referencing FDA approval, with potential UK... ► Artikel lesen | |
| IBIO | 3,830 | -6,70 % | iBio, Inc.: iBio Reports Fiscal Second Quarter 2025 Financial Results | SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), today reported financial results for the second quarter ended Dec. 31, 2024, and provided a corporate update on its progress.... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,258 | +0,87 % | Arbutus Biopharma Corporation: Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update | Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation scheduled for September... ► Artikel lesen | |
| MANNKIND | 4,349 | -5,93 % | MannKind Corp. Q4 Earnings Summary | WASHINGTON (dpa-AFX) - Below are the earnings highlights for MannKind Corp. (MNKD):Earnings: $7.42 million in Q4 vs. $1.40 million in the same period last year.
EPS: $0.03 in Q4 vs. $0.00... ► Artikel lesen | |
| ALDEYRA | 1,350 | -72,49 % | XFRA 137: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILALDEYRA THERAPEUT.DL-... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 2,655 | -4,15 % | Lucid Capital Markets sets $14 target on Cardiff Oncology stock | ||
| TRAWS PHARMA | 4,490 | -100,00 % | Traws Pharma, Inc.: Traws Pharma Reports Full Year 2024 Results and Business Highlights | Tivoxavir marboxil's potential as a single dose therapeutic agent for bird flu supported by significant antiviral activity in three well accepted animal models and positive Phase 1 data Ongoing... ► Artikel lesen | |
| CARISMA THERAPEUTICS INC | 0,282 | +36,66 % | Carisma winds down operations, lays off 95% of remaining staff |
SERA PROGNOSTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -7,83 % bei einem Aktienkurs von 3,180 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SERA PROGNOSTICS INC finden Sie auf Wallstreet Online.
